NCT00093782View on ClinicalTrials.gov

Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Metastatic Gastrointestinal Carcinoid TumorPulmonary Carcinoid TumorRecurrent Gastrointestinal Carcinoid TumorRecurrent Islet Cell Carcinoma
Interventions
DRUG

temsirolimus

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

M5G 2M9

Princess Margaret Hospital Phase 2 Consortium, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00093782 - Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma | Biotech Hunter | Biotech Hunter